BlissBio Nets Over CNY 100 Mn in Series B+
BlissBio (Chinese: 百力司康) announced that it had completed a CNY 100 million Series B+ financing round, which was led by In Capital (Chinese: 约印医疗基金) and followed by its existing investors Oriental Fortune Capital (Chinese: 东方富海) and Sherpa Healthcare Partners (Chinese: 夏尔巴资本). Proceeds raised in this round will be used in the advancement of clinical research of BB-1701, BB-1705, BB-1709 programs, pre-clinical research and registration of product pipelines, and the preparation of new drug application. BB-1701 is a new antibody-drug conjugate (ADC) under Phase II clinical trial. Its toxin Eribulin, licensed from Eisai, is an oncology product on the market with clinically proven safety and efficacy profiles.
Briefing Feb 16, 2023 12:51 PM
· Healthcare
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
In-depth
Briefing Feb 07, 2023 10:59 AM
· Healthcare
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Briefing Jan 30, 2023 10:44 AM
· Healthcare
Levostar Completes Pre-A Financing Round to Further Invest in CGT
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Briefing Aug 31, 2022 08:30 PM
· Healthcare
Enitiatebio Nets One Hundred Million of CNY in Series A Round
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
See more
Read next
Insight
In-depth
Consumer Discretionary, Financials, Technology · Analysis
EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part II）
Yesterday 10:00 AM
Insight
In-depth
Insight
In-depth